Legal Representation
Attorney
Colleen Ganin
USPTO Deadlines
Next Deadline
1924 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-12)
Due Date
November 12, 2030
Grace Period Ends
May 12, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 28, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 28, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Feb 28, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 28, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 12, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 12, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 10, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 10, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 9, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 9, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 9, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 9, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Aug 5, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Aug 5, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 5, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Feb 7, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 5, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 8, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 13, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 13, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 24, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 9, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 9, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 9, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 9, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 9, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 1, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 1, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 1, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 4, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 27, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 9, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Promoting public awareness about cancer; promoting public awareness about chimeric antigen receptor T cell therapy; promoting public awareness about research, detection, diagnosis, and medical treatments in the fields of pharmaceuticals, cell therapies, chimeric antigen receptor T cell therapy, oncology, and cancer
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Class 042
Providing information about medical research in the field of cancer; providing information about medical research in the field of chimeric antigen receptor T cell therapy; medical and scientific research in the field of cancer treatment and chimeric antigen receptor T cell therapy
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Class 044
Providing medical information in the field of cancer; providing medical information in the field of chimeric antigen receptor T cell therapy; providing medical information about research, detection, diagnosis, and medical treatments in the fields of cancer, immunotherapy,
pharmaceuticals, oncology, cell therapies, and chimeric antigen receptor T cell therapy via a website
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Additional Information
Pseudo Mark
CAR THERAPEUTICS TOGETHER
Classification
International Classes
035
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CAR T"